18/11/2026, Wednesday12:38

Menu

EDITION   :

TRTRENENARARFRFRRURUURUR

Notifications

You have no new notificationsHome
Turkish Aerospace Industries CEO Mehmet Demiroglu said Spain plans to purchase 15 additional Hurjet trainer aircraft after signing a deal for 30 of the Turkish-made supersonic jets, with deliveries to the European nation scheduled to begin in 2028.ASELSAN announced that its GOKALP Counter-UAV System successfully destroyed a target drone using a hit-to-kill interceptor during a live demonstration at the company's Ogulbey Technology Base, marking the entry of a fully mobile and cost-effective solution into Türkiye's autonomous air defense portfolio.President Recep Tayyip Erdogan on Friday criticized the existing global order and the United Nations, warning that binding international accords and judicial rulings are increasingly ignored while the UN system lacks legitimacy for failing to reflect the will of the global community.Foreign Minister Hakan Fidan said Thursday that Ankara has finalized preparations to submit the Mecca defense agreement to parliament for approval, stressing that the pact provides for mutual defense and does not authorize attacks or troop deployments to other countries.The Royal Swedish Academy of Sciences on Wednesday awarded the 2026 Nobel Prize in Chemistry to Henri Kagan and Kenso Soai for discoveries explaining how molecular asymmetry essential to life emerges through autocatalysis, resolving a century-old mystery about homochirality with significant implications for drug development.

Two Ebola vaccine candidates to begin phase 2 trials in DRC next week

Yenişafak English AA12:15, 18/11/2026, Wednesday
AA
Ebola virüsünün Bundibugyo türüne karşı geliştirilen iki aday aşı, Tumani denemesinin 2. fazına geçmek üzere onay aldı; testlerin Bunia'da 26 veya 27 Kasım'da başlaması bekleniyor.

The World Health Organization said two experimental vaccines developed specifically against the Bundibugyo Ebola virus received approval to advance to phase 2 of the Tumani trial, with testing expected to begin in Bunia on Nov. 26 or 27.

Two candidates cleared for phase 2

The World Health Organization (WHO) said on Tuesday that two experimental vaccines developed specifically against the Bundibugyo Ebola virus are expected to begin phase 2 clinical trials next week in the Democratic Republic of the Congo. Speaking at a WHO news conference in Geneva, Dr. Meg Doherty said the candidates received approval last week to advance to phase 2 of the Tumani randomized controlled trial.

The first vaccine, ChAdOx1, was developed by Oxford University and the Serum Institute of India, while the second comes from Moderna. “Both of them last week were provided approval to move into phase two,” Doherty said.

Testing timeline and trial design

Testing was expected to begin Nov. 26 or 27 in Bunia, where the trial is operating, Doherty said. The second phase will assess vaccine safety and immunogenicity, or the ability to trigger an immune response, and candidates meeting the required criteria will advance to phase 3, where researchers will evaluate their effectiveness against a comparator.

The Tumani trial, launched Oct. 23, is designed to accommodate additional vaccine candidates as they become available. More than 140 participants have already enrolled, with thousands expected to participate as researchers expand testing to additional sites and deploy mobile teams, according to the WHO expert.

Outbreak figures and obstacles

WHO Director-General Tedros Adhanom Ghebreyesus highlighted progress in vaccine development amid the Ebola outbreak. “We expect two candidate vaccines developed specifically for Bundibugyo virus to begin testing as early as next week,” he said, adding that the outbreak had surpassed 11,300 cases and 5,500 deaths, with between 400 and 500 new infections still being reported weekly.

Tedros warned that insecurity, attacks on health workers and delays in identifying infections continued to undermine efforts to contain the epidemic. He explained that “such attacks also discourage people from seeking care in an Ebola treatment center.”

Comments

Comments you share on our site are a valuable resource for other users. Please be respectful of different opinions and other users. Avoid using rude, aggressive, derogatory, or discriminatory language.